Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid #cancer to radioiodine therapy (SEL-I-METRY): protocol for a multicentre UK single arm phase II trial https://t.co/ULe3qH3hsB #th
1,318 followers
10,666 followers
RT @ButterflyThyro: Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated…
839 followers
Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol for a multicentre UK single arm phase II trial | BMC Cancer | Full Text ht
1,619 followers
New from #CR_UK https://t.co/up1JLBaotu Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol for a multicentre UK single arm pha